HC Wainwright Reiterates “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 148.45% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Oppenheimer increased their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, JMP Securities began coverage on Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.67.

Astria Therapeutics Trading Up 2.1 %

Shares of NASDAQ:ATXS opened at $6.44 on Thursday. Astria Therapeutics has a 52 week low of $6.20 and a 52 week high of $16.90. The company’s 50 day moving average is $7.70 and its two-hundred day moving average is $9.89. The company has a market cap of $363.43 million, a PE ratio of -3.08 and a beta of 0.67.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ATXS. Charles Schwab Investment Management Inc. grew its stake in Astria Therapeutics by 152.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock worth $3,460,000 after buying an additional 189,727 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $613,000. FMR LLC grew its position in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares during the last quarter. Barclays PLC increased its holdings in shares of Astria Therapeutics by 70.5% in the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after acquiring an additional 38,321 shares during the period. Finally, Vestal Point Capital LP increased its holdings in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.